Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer in the Era of Personalized Medicine

2015 ◽  
Vol 33 (5) ◽  
pp. 524-524 ◽  
Author(s):  
Bivas Biswas
Keyword(s):  
Lung Cancer ◽  
Personalized Medicine ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

2012 ◽  
Vol 7 (10) ◽  
pp. 1594-1601 ◽  
Author(s):  
Vassiliki A. Papadimitrakopoulou ◽  
Jean-Charles Soria ◽  
Annette Jappe ◽  
Valentine Jehl ◽  
Judith Klimovsky ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer

2017 ◽  
Vol 12 (1) ◽  
pp. S1229-S1230
Author(s):  
Nikhil Pande ◽  
Amit Joshi ◽  
Vanita Noronha ◽  
Vijay Patil ◽  
Anuradha Chougule ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?

Lung Cancer ◽  
2010 ◽  
Vol 68 (3) ◽  
pp. 433-437 ◽  
Author(s):  
Mario Scartozzi ◽  
Paola Mazzanti ◽  
Riccardo Giampieri ◽  
Rossana Berardi ◽  
Eva Galizia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Predictive Factors ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line ◽  
Nsclc Patients

scholarly journals Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer

2013 ◽  
Vol 8 (3) ◽  
pp. 369-372 ◽  
Author(s):  
Suresh S. Ramalingam ◽  
Taofeek K. Owonikoko ◽  
Madhusmita Behera ◽  
Janakiraman Subramanian ◽  
Nabil F. Saba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer: a pilot study

2008 ◽  
Vol 55 (3,4) ◽  
pp. 260-266
Author(s):  
Naoki Nishimura ◽  
Rika Sugiura ◽  
Hirotaka Ueda ◽  
Hiroshi Ono ◽  
Hidehito Horinouchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pilot Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Combination Chemotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line
Sign in / Sign up

Export Citation Format

Share Document